Xspray Pharma Raises SEK 113 Million in Oversubscribed Rights and Over-Allotment Issues

Xspray Pharma AB ( (SE:XSPRAY) ) has provided an announcement.

Xspray Pharma has completed an oversubscribed rights issue, with subscriptions reaching about 258 percent of the offered shares, prompting the board to fully utilize an over-allotment issue. Together, the rights and over-allotment issues will raise approximately SEK 113 million before costs, increasing the company’s share capital and expanding the total number of shares to 47,416,574.

The additional funding is earmarked to finalize preparations and support the planned launch of Xspray’s lead oncology candidates Dasynoc and Nilopki, including building a commercial organization with Eversana, launch inventory and distribution. Proceeds will also back further pipeline development and manufacturing improvements, and based on current plans are expected to cover working capital needs through 2026, reinforcing Xspray’s financial position ahead of key regulatory and launch milestones.

More about Xspray Pharma AB

Xspray Pharma AB is a Swedish specialty pharmaceutical company focused on developing optimized versions of existing cancer therapies using innovative formulation technology. Its lead product candidates, Dasynoc and Nilopki (an optimized version of nilotinib/Tasigna), target oncology indications, with commercialization planned in partnership with Eversana and a focus on the U.S. and global specialty pharma markets.

Average Trading Volume: 50,815

Technical Sentiment Signal: Sell

Current Market Cap: SEK1.28B

See more insights into XSPRAY stock on TipRanks’ Stock Analysis page.